Nephrol Dial Transplant (2001) 16: 1756-1760
© 2001 European Renal Association-European Dialysis and Transplant Association
Editorial Comments
Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab
Servicio de Nefrología, Hospital Ramón y Cajal, Universidad de Alcalá, Madrid, Spain
Keywords: basiliximab; daclizumab; monoclonal antibodies
At present, classical induction therapy is inadvisable for low-risk renal transplantation (RT) recipients, given the efficacy of immunosuppressive regimens based on micro-emulsified cyclosporin, tacrolimus, MMF, or sirolimus and the risk of infections and malignancies [1]. The classical induction is more questionable for high immunological risk patients. Monoclonal antibodies against IL-2 receptor (IL-2r) offer the possibility of more selective immunosuppression.
Murine anti-IL-2r antibodies significantly reduce the incidence of early acute rejection without any relevant associated toxicity [2]. However, they stimulate a potent immune response in the human recipient that limits their use at medium or long-term, exhibit a half-life and are inefficient to destroy human cells.
A chimeric anti-IL-2r antibody: basiliximab
Basiliximab is a chimeric monoclonal antibody (murine/human) with human IgG1 constant heavy chain regions and kappa light chain. It specifically binds and blocks CD25 antigen, IL-2r 
-chain, at the surface of activated T-lymphocytes [3]. This specific basiliximab binding to
A humanized anti-IL-2r antibody: daclizumab
The problem of dosage
Conclusions
Notes
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Ruggenenti, I. Codreanu, P. Cravedi, A. Perna, E. Gotti, and G. Remuzzi Basiliximab Combined with Low-Dose Rabbit Anti-Human Thymocyte Globulin: A Possible Further Step toward Effective and Minimally Toxic T Cell-Targeted Therapy in Kidney Transplantation Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 546 - 554. [Abstract] [Full Text] [PDF]
|
|